Talus Bioscience combines functional proteomics, automated biology, and machine learning to target transcription factor proteins driving cancer and beyond.

Talus Bioscience

Talus Bioscience is a venture-backed early-stage biotechnology startup company working on drug development for gene regulators. Talus Bio spun out of two leading institutions in September 2020 (University of Washington and Altius Institute for Biomedical Sciences) and is located in Seattle, WA. We are building a data-enabled drug development platform that will focus primarily on small-molecule drug development in oncology. 

Talus Bio's platform measures a drug’s ability to disrupt a gene regulator within its natural, non-engineered cellular environment. Furthermore, a single experiment using the platform measures activity for about 1,000 gene regulators simultaneously, providing information on in-cell drug activity and specificity in a single experiment. To accomplish this, we combine innovative cell processing with high-sensitivity quantitative proteomics and advanced downstream analytics.

As a company, Talus Bio focuses on two parallel efforts to prove that our technology can open up the world of gene regulation for drug discovery:

- Developing internal programs against previously undruggable gene regulators in 
 cancers with poor standard of care
- Partnering with pharma, biotech, and academic labs to help progress their pipeline of gene regulator drugs

National Science Foundation

National Institutes of Health

Andy Hill Cancer Research Endowment (CARE) Fund

Y Combinator

Fifty Years

FundersClub

Pioneer Fund

North South Ventures

Farvatn Venture

Reinforced Ventures

Talus Bio

Thanks to World Industry News for including Talus Bio on your list of notable proteomics companies!

Don’t miss this opportunity to hear a great proteomics discussion including one of the world’s leading experts, Talus Bio CTO Lindsay Pino!

What a great week at BIO 2024 in San Diego! The Talus Bio team stayed very busy with 2 company presentations, 24 partnering meetings, and countless networking receptions. It was an amazing opportunity to connect with current and potential pharma partners, investors, and scientific colleagues!

Talus Bio is getting very excited about the American Society For Mass Spectrometry (ASMS) Annual Conference that starts this weekend, and we'll be very well represented! If you're attending the conference, be sure to check out one (or all) of the great opportunities to learn more about the cutting-edge transcription factor drug discovery powered by AI being done at Talus Bio presented by William Fondrie, Lindsay Pino, Daniele Canzani, PhD, Sebastian Paez, Andrea Gutierrez, and Julia Robbins.

I'm looking forward to this!

Transforming Healthcare and Drug Discovery with Artificial Intelligence (AI)
Presenting by HBA Seattle
May 20th, 2:00 - 5:30 pm at Adaptive Biotechnologies Corp.

Speakers:
Shweta Maniar Global Director, Healthcare & Life Sciences at Google Cloud
Jeremy Forman, VP, R&D, Data, & Analytics at Pfizer (Seagen)
Kate Ostbye, Director, Enterprise Data Science and Machine Learning at Pfizer (Seagen)

Registration link: https://bit.ly/3vLZz5x

Such a great Day 1 at the Life Science Innovation Northwest conference today! Alex Federation, CEO and Co-Founder of Talus Bio gave an excellent presentation in the Oncology session. Looking forward to Day 2!

CrUX Dataset

CloudFront

CrUX Top 10m

SiteGround CAPTCHA

Business Management

Alex Federation

Co-Founder and CTO

Lindsay Pino

Chief Operating Officer

Michelle L. Briscoe

Finance and Administration

Eloma Dosawat

Lab Operations Manager

Margaux McBirney

Operations Manager

Megan Fritz

Manager, Computational Biology

William Fondrie

Data Analyst

Carolyn Allen

Senior Research Associate

Julia Robbins

Pauliina Talus

J. Seth Strattan

Omri Amirav-Drory

Milad Alucozai

Michelle Briscoe

COO and CFO

United States Biotechnology Companies with Seed Funding

Y Combinator Portfolio Companies

Startups Founded in 2020 (Top 10K)

United States Companies With More Than 10 Employees (Top 10K)

Talus Bio is a drug discovery biotech startup working on drug development for gene regulators. The company integrates functional proteomics, automated biology, and machine learning to target challenging cancer transcription factors. The MARMOT (Multiplexed Assays for the Rational Modulation Of Transcription Factors) platform, developed by the company, leverages AI, advanced proteomics, synthetic chemistry, and computational biology to design and analyze drugs, proteins, and genomics in a groundbreaking manner.

Two Bear Capital

Seed Round - Talus Bio

NCATS

Grant - Talus Bio

National Institute of Health

National Cancer Institute

Pre Seed Round - Talus Bio

Seattle

Washington

United States

North America

Talus Bioscience Raises $11.2M in New Funding

Talus Bio tacks on $11M to target hard-to-reach transcription factors

Outstanding LGBTQ+ Voices: Michelle Briscoe - Puget Sound Business Journal

Outstanding LGBTQ+ Voices: Michelle Briscoe, Talus Bio - Puget Sound Business Journal

Celestine “Cee Cee” Schnugg’s Post

Michelle Briscoe on LinkedIn: Talus Bio will have a very strong presence at the ASMS conference next…

Kirkland-based Resolution Bioscience closing 2 years after ...

A functional proteomics platform for targeting transcription factors in live cells, enabling drug discovery for diseases like cancer and diabetes.

Development of inhibitors targeting transcription factors for conditions such as rhabdomyosarcoma and neuroblastoma.

Development of the first inhibitor for a transcription factor driving chordoma, a type of spinal cord cancer.

Talus Bio collaborates on chemistry and disease models involving transcription factors for drug target discovery.

India

Asia

Malaysia

Morocco

Africa

Germany

Europe

HTML5

Lightbox

Wordpress

Google Fonts

Google Analytics

Modernizr

Google Compute Engine

jQuery

Adobe Fonts

F5 NGINX

news_impact_assignment_basic

key_people

merger_acquisitions

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Aug 21, 2024 5:10 AM	01c0eb3a
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general
crunchbase trigger	general	Nov 25, 2024 9:06 AM	52ba5c2d
crunchbase profile	general	Nov 25, 2024 9:30 AM	7b64bcd6
li profile	general	Aug 21, 2024 5:10 AM	e534ba9b
translate crunchbase fundingrounds	general	Nov 25, 2024 2:02 PM	fac691a7
peers	general	Aug 21, 2024 5:10 AM	13fc3e0b
news basic	general	Aug 21, 2024 5:10 AM	9d4c3966
bundesanzeiger	filings
financials download nd	financials
private financials	financials

BIO:TALUS

Talus Bioscience